Oseltamivir: here's the fair price
This is what US pharmacies pay, on average, for oseltamivir. Use it to spot a fair cash price, and feel good about asking for one.
Oseltamivir Phos 30 Mg Capsule
A fair cash price is usually this cost plus a dispensing fee. If your quote is many times higher, ask about a generic, another pharmacy, or a cash discount.
Ask for generic Oseltamivir Phos 30 Mg Capsule. Pharmacies pay about $19.33 for 30. Ask your pharmacy for its cash price and compare it with your copay. A fair cash price is close to this cost plus a dispensing fee.
Source: CMS NADAC as of 2026-11-04. Ask your prescriber or pharmacist whether a generic is right for you.
Source: CMS NADAC weekly file as of 2026-11-04. Median across NDCs with the same description. Public domain.
Your ZIP and location stay in your browser. We never store them.
Every strength and form
| Product | Pharmacy cost | 30 count | Effective |
|---|---|---|---|
| OSELTAMIVIR 6 MG/ML SUSPENSIONGeneric | $0.16 per mL | n/a | 10/21/2026 |
| OSELTAMIVIR PHOS 30 MG CAPSULEGeneric | $0.64 per tablet or capsule | $19.33 | 10/21/2026 |
| OSELTAMIVIR PHOS 75 MG CAPSULEGeneric | $0.80 per tablet or capsule | $23.94 | 10/21/2026 |
| OSELTAMIVIR PHOS 45 MG CAPSULEGeneric | $0.82 per tablet or capsule | $24.47 | 10/21/2026 |
Source: CMS NADAC, as of 2026-11-04. National average acquisition cost, not a retail quote.
Label basics
What it is used for (FDA label)
1 INDICATIONS AND USAGE Oseltamivir phosphate capsule is an influenza neuraminidase inhibitor (NAI) indicated for: Treatment of acute, uncomplicated influenza A and B in patients 2 weeks of age and older who have been symptomatic for no more than 48 hours. (1.1) Prophylaxis of influenza A and B in patients 1 year and older. (1.2) Limitations of Use : Not a substitute for annual influenza vaccination. (1.3) Consider available information on influenza drug susceptibility patterns and treatment effects when deciding whether to use. (1.3) Not recommended for patients with end-stage renal disease not undergoing dialysis. (1.3) 1.1 Treatment of Influenza Oseltamivir phosphate capsules are...
Common side effects (FDA label)
6 ADVERSE REACTIONS The following important adverse reactions are described below and elsewhere in the labeling: Serious skin and hypersensitivity reactions [see Warnings and Precautions (5.1)] Neuropsychiatric events [see Warnings and Precautions (5.2)] Most common adverse reactions (>1% and more common than with placebo): Treatment studies - Nausea, vomiting, headache. (6.1) Prophylaxis studies - Nausea, vomiting, headache, pain. (6.1) To report SUSPECTED ADVERSE REACTIONS, contact FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are...
Drug interactions (from the label)
7 DRUG INTERACTIONS Live attenuated influenza vaccine (LAIV), intranasal: Avoid administration of LAIV within 2 weeks before or 48 hours after oseltamivir phosphate capsules, use, unless medically indicated. (7) 7.1 Influenza Vaccines Live Attenuated Influenza Vaccine The concurrent use of oseltamivir phosphate capsules with live attenuated influenza vaccine (LAIV) intranasal has not been evaluated. However, because of the potential for oseltamivir phosphate capsules to inhibit replication of live vaccine virus and possibly reduce the efficacy of LAIV, avoid administration of LAIV within 2 weeks before or 48 hours after oseltamivir phosphate capsules administration, unless medically...
Warnings (from the label)
5 WARNINGS AND PRECAUTIONS Serious skin/hypersensitivity reactions such as Stevens-Johnson Syndrome, toxic epidermal necrolysis and erythema multiforme: Discontinue oseltamivir phosphate capsules and initiate appropriate treatment if allergic-like reactions occur or are suspected. (5.1) Neuropsychiatric events: Patients with influenza, including those receiving oseltamivir phosphate capsules, particularly pediatric patients, may be at an increased risk of confusion or abnormal behavior early in their illness. Monitor for signs of abnormal behavior. (5.2) 5.1 Serious Skin/Hypersensitivity Reactions Cases of anaphylaxis and serious skin reactions including toxic epidermal necrolysis,...
Source: FDA drug label via openFDA, label effective 2023-01-30. Full label on DailyMed. Excerpts are verbatim and truncated. Read the full label and ask your pharmacist.